NK1 receptor antagonists: all 244 studies that test it

Page 1 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Aprepitant for the Treatment of CLIFAHDDRecruitingNCT07845825Early Phase 1
• Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsRecruitingNCT07762287Phase 1
• Aprepitant to Improve Same Day Discharge for TKANot yet recruitingNCT07639723Phase 4
• Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryNot yet recruitingNCT07371728Phase 4
• Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer PatientsNot yet recruitingNCT06931119Phase 1
• Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and MetoclopramideNot yet recruitingNCT06740812Phase 4
• Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingNCT06543966Phase 3
• Antiemetic Fosaprepitant To Remedy Nausea and VomitingRecruitingNCT06382012Phase 2/3
• Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryRecruitingNCT06357234Phase 2
• Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingNCT05841849Phase 4
• Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV PreventionEnrolling by invitationNCT05773950Not applicable
• Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCCNot yet recruitingNCT05711823Phase 3
• A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopauseCompletedNCT06112756Phase 2Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerActive, not recruitingNCT05587296Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)CompletedNCT05099159Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05042362Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05030584Phase 3Results posted
• Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataCompletedNCT04606264Phase 3Results posted
• Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)CompletedNCT04054193Phase 4Results posted
• Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown OriginCompletedNCT03841331Phase 2Results posted
• A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaCompletedNCT03836001Phase 2Results posted
• Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedNCT03677401Phase 3Results posted
• A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor SymptomsCompletedNCT03596762Phase 2Results posted
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyCompletedNCT03578081Phase 3Results posted
• Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedNCT03546816Phase 3Results posted
• Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)TerminatedNCT03540160Phase 3Results posted
• Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve GastrectomyCompletedNCT03435003Phase 4Results posted
• Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque PsoriasisCompletedNCT03343639Phase 2Results posted
• Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic CoughCompletedNCT03282591Phase 2Results posted
• Low Dose Aprepitant for Patients Receiving CarboplatinTerminatedNCT03237611Phase 2Results posted
• Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General AnesthesiaCompletedNCT03197064Phase 4Results posted
• Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and TemozolomideCompletedNCT02991456Phase 2Results posted
• Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose MelphalanCompletedNCT02939287Phase 3Results posted
• Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor SymptomsCompletedNCT02865538Phase 1/2Results posted
• Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving ChemotherapyTerminatedNCT02732015Phase 2Results posted
• Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB PatientsCompletedNCT02654483Phase 2Results posted
• Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) ProphylaxisCompletedNCT02625181Not applicableResults posted
• Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)TerminatedNCT02519842Phase 3Results posted
• Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and DependenceCompletedNCT02210195Phase 2Results posted
• A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)CompletedNCT02196324Phase 2Results posted
• Effect of Chronic ACE and DPP4 Inhibition on Blood PressureCompletedNCT02130687Not applicableResults posted
• Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving ChemotherapyCompletedNCT02097823Phase 2Results posted
• Topical Aprepitant in Prurigo PatientsCompletedNCT01963793Phase 2Results posted
• Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell CarcinomaTerminatedNCT01874119Phase 2Results posted
• Differentiating the Effects of Substance P and Beta-endorphinCompletedNCT01854177Not applicableResults posted
• Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell TumorsCompletedNCT01736917Phase 2Results posted
• A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)CompletedNCT01732458Phase 2Results posted
• Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)CompletedNCT01697579Phase 2Results posted
• A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)CompletedNCT01636947Phase 4Results posted
• Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary SyndromeTerminatedNCT01625455Phase 4Results posted
• Treatment for Cannabis Withdrawal and DependenceCompletedNCT01611948Phase 2Results posted
• Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)CompletedNCT01594749Phase 3Results posted
• The Role of Substance P on Perception of Breathlessness During Resistive Load BreathingCompletedNCT01580423Not applicableResults posted
• Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic CancerCompletedNCT01534637Phase 2Results posted
• Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination ChemotherapyCompletedNCT01504711Not applicableResults posted
• Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyCompletedNCT01500226Phase 3Results posted
• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01500213Phase 3Results posted
• Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedNCT01499849Phase 3Results posted
• Fosaprepitant in Patients Receiving Ifosfamide-based RegimenCompletedNCT01490060Not applicableResults posted
• Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and VomitingCompletedNCT01474915Phase 4Results posted
• Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving TemozolomideCompletedNCT01450826Phase 2Results posted
• Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and VomitingCompletedNCT01432015Phase 4Results posted
• Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)TerminatedNCT01405924Phase 2Results posted
• A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)CompletedNCT01362530Phase 3Results posted
• Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyCompletedNCT01334086Phase 2Results posted
• Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.CompletedNCT01298193Phase 4Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot StudyTerminatedNCT01183481Phase 2Results posted
• Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin TrialCompletedNCT01149369Phase 2Results posted
• Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By ChemotherapyTerminatedNCT01031953Phase 1/2Results posted
• Aprepitant Effects on Oxycodone ResponseCompletedNCT00999544Not applicableResults posted
• A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)CompletedNCT00990821Phase 1Results posted
• Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)CompletedNCT00952341Phase 3Results posted
• A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)CompletedNCT00945321Phase 1Results posted
• The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSDCompletedNCT00896038Phase 2Results posted
• Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation TherapyTerminatedNCT00895245Phase 2Results posted
• Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective HysterectomyTerminatedNCT00888329Phase 4Results posted
• A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)CompletedNCT00819039Phase 1Results posted
• A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)TerminatedNCT00818259Phase 1Results posted
• A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) PancreatitisCompletedNCT00736073Not applicableResults posted
• Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having CraniotomyCompletedNCT00734929Phase 4Results posted
• Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and VomitingCompletedNCT00717054Not applicableResults posted
• Emend for Multiple-day Emetogenic ChemotherapyCompletedNCT00711555Phase 2Results posted
• Aprepitant for PONV Prophylaxis in Outpatient Plastic SurgeryCompletedNCT00659945Phase 4Results posted
• Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma PatientsCompletedNCT00651755Not applicableResults posted
• Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)CompletedNCT00619359Phase 3Results posted
• A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.CompletedNCT00601172Phase 3Results posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell TumorsCompletedNCT00572572Phase 3Results posted
• Substance P Antagonist in the Treatment of Posttraumatic Stress DisorderCompletedNCT00383786Phase 2Results posted
• Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOXCompletedNCT00381862Phase 2Results posted
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)CompletedNCT00337727Phase 3Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell TransplantCompletedNCT00248547Not applicableResults posted
• A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)CompletedNCT00231777Phase 3Results posted
• Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompletedNCT07248280Phase 3
• Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingCompletedNCT06932107Phase 3
• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruitingNCT06780085Phase 2
• Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid CancerCompletedNCT06697782Phase 4
• Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary DysmenorrheaCompletedNCT06317064Phase 3

← NK1 receptor antagonists overview